|
Budget
2006: Will it deliver?
Indian Pharma is at an inflection point and the industry needs
a dream budget, more than ever, to get back on its growth
path. Deepali Gupta talks to the industry associations about
their expectations from the forthcoming budget.
Upfront
Wyeth,
GVK Bio ink research deal
In an R&D outsourcing deal, the pharma multinational,
Wyeth Pharmaceuticals and GVK Biosciences (GVK Bio), have
entered into a research partnership agreement to provide a
range of research services in the synthetic chemistry area.
Indian
Pharma going strong in third quarter
Indian pharma companies are taking forward their winning streak
this quarter with companies like Sun Pharma, Ajanta and Lupin
registering robust sales. Nicholas Piramal too put forth good
sales figures this quarter even though its net profits went
down due to product withdrawals.
Indoco's
facility secures USFDA approval
Indoco Remedies announced that it has received USFDA approval
for its sterile ophthalmic preparations facility in Goa. This
facility will be involved in the production and export of
the company's ophthalmic preparations to USA.
A
trip to European markets
The ninth Indian Drug Manufacturers' Association (IDMA)-APA
Pharmaceutical Analysts Convention was an event of high standards.
In fact, standards is all they talked about. Sonal Shukla
takes us through the technical and the scientific aspects
of ‘New Features and the Latest Developments in the European
Pharmacopoeia’
IPR
is India's ticket to global markets
India will emerge as a leading country in the world pharmaceutical
market over the next 10 years. This sentiment echoed at the
session on 'IPR Interactive Media Round Table', organised
by Interpat India Task Force on February 2, 2006 at ITC Grand
Maratha Sheraton.
Stock
Watch
Orchid
Chemicals and Pharmaceuticals
Orchid reported a 38 percent y-o-y growth in sales of Rs 2.38
billion.
|
